Unknown

Dataset Information

0

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer.

ABSTRACT:

SUBMITTER: Okines DAF 

PROVIDER: S-EPMC8315337 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer.

Okines Dr Alicia Fc DAF   Parton Dr Marina DM  

The Lancet regional health. Western Pacific 20210609

Similar Datasets

Unknown De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer.
| S-EPMC7994398 | biostudies-literature
Unknown Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies.
| S-EPMC9221124 | biostudies-literature
Unknown HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?
| S-EPMC10968736 | biostudies-literature
Unknown HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping.
| S-EPMC8833556 | biostudies-literature
Unknown RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
| S-EPMC9769189 | biostudies-literature
Unknown Adjuvant Chemotherapy in Lymph Node-Negative, T1 Triple-Negative Breast Cancer.
| S-EPMC12585342 | biostudies-literature
Unknown Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
| S-EPMC4313867 | biostudies-literature
Unknown De-escalation in breast cancer surgery.
| S-EPMC8866473 | biostudies-literature
Unknown De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.
| S-EPMC9328618 | biostudies-literature
Unknown Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
| S-EPMC9482917 | biostudies-literature